This research study is evaluating the effect of AMR101 as a possible chemopreventive agent to
reduce risk of colorectal cancer in individuals with a history of colorectal adenoma.
- The name of the study drug involved in this study is:
-- AMR101 (VASCEPA).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Harvard Medical School Massachusetts General Hospital
Collaborators:
Harvard School of Public Health National Institutes of Health (NIH)